⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSTV News
PLUS THERAPEUTICS, Inc. Common Stock
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
globenewswire.com
PSTV
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
globenewswire.com
PSTV
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
globenewswire.com
PSTV
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
globenewswire.com
PSTV
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
globenewswire.com
PSTV
Plus Therapeutics Expands CNSide Assay Platform to State of California
globenewswire.com
PSTV
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
globenewswire.com
PSTV
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
globenewswire.com
PSTV
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
globenewswire.com
PSTV
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
globenewswire.com
PSTV